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Coronary rngioplasty is being incrcasiqly used 8s the primaty 
treatmemt for patlet& with acutt mpardial inhrctka, but 
conhversy remains ovc7 its potcnG8l M ia prdeiwKc (0 
Uwada@sis as sIaadrrd care. This rtpod summarizes tbc 
pnMishal evideme on health ou~cows after primary rngioplasly 
campared with Huoabdysis or no intmdon for patkob with 
acute nyoardial iafarctioa. The data t&k5 presenkd plw;dc 
the scieetilk p,amdwd (0 assirc plIysiciaas and other policy- 
makers in decidie rrhkb iatcrvcntiaa Lo provide for broad 
populations of patids. 
IJ Am Cd Cat&d 1996;27:737-50) 
Over the past decade, coronary angioplasty has bcen increas- 
ingly used as initial and immediate treatment for ppticnb with 
acute myocardial infarction. However. most patients with acute 
myocardial infarction present to hospitals without cardiac 
catheterization !aboratorier. There remains controversy over 
whether primary angioplasty should be adopted in preference 
to thrombolysis as standard care. Deciding which intervention 
to provide for broad populations of patients should ideally be 
based on the scientific evidence on outcomes. 
Searches for English-language publications referenced in 
MEDLINE were conducted by two physicians for key ques- 
tions. The reference lists of art&s identified in the initial 
computerized searches were used to identify other key refer- 
ences. Abstrxts and review articles were read for relevant 
references and information but in general were not included in 
the evidence tables. Because there are xant published long- 
term data from the four randomized controlled triah of 
primary angioplasty. one imcaigator from each trial was 
contacted to ask whether l-year follow-up data were available. 
The evidence tables and figures address the following key 
questions: 
Qtlsthl 1. EKchshs f&ml intematioa mile 1). of all 
patients pre5enting with true my0xdial Infarction. whal propor- 
tions are eligible for I) primary angioplasty or 2) thrornbol$! 
QKSGDII 2. h-bqild mrtalii (Tab& 2). what is the 
in-hospital mortality rate after I) primary angioplasty, 2) throm- 
holy& or 3) no intervention among patient.5 * are a) eligible 
for either primary ar@oplasty or thrombolys& b) at risk for 
Fnlm the Divikt d Rcscarch. The Pcrmancntc Mcdicd Gray. Inc.. 
OaklaM and ‘Sam Francinu [X’paflmcnt of Putrlii k&h and tDGw of 
Cw.lii. Dcparimcnl of Metine. lhcnity of CalXomia. San Fnnmm. 
Califrdd. 
v-m: Dr. Tracy A LA, Dinun d Resurck The 
Pmnanmtr Medic-a! Chup. IIK, 3.95 Eha~lway. Oakland Catilomia 9451 I. 
hlceding (i.c.. not eligible for thrtwbotysls): c) in cdiogenic 
shcck on presentation. 
Figure 1 shows in-hospital mortality after primary angio- 
plastv cumpared with thrombolysis in recent studies. Figure 2 
summarizes in-hospital mortality after thrombol-ysis compared 
with control interventions in selected studies. Figure 3 includes 
studies on cardiogcnic shock. comparing primary angioplasty 
with no intervention. 
Qaestion 3.0&r end points. Among patients eligible for 
either primary angioplasty or thrombolys&, what are the 
following outcomes after I) primary angioplasty, 2) thrombol- 
ysis. or 3) no intervention? Long-term survival rates arc: shown 
in Table 3. Figure 4 summarizes the resul& of these studies. 
Fipe I. In-hptal mortality rate+ for randtnnizcd, cw~~rolkd triak 
1.1 primav angioplauy and rhromhol+ Nlubm b W ur 
I .fcrencc numtrn. FAMI = Primary Anpioplasty Myocardial Infarc- 
16% 1 -- Fmrc 2. In-hmpiral monaliry ratcb for random- ized. rrmtrollcd rrialx of thmmhulysls 31 ‘3 weeks; “3 days. .Xl dqs or I monrh: and “‘42 days. 
Numbers in ?warkcls arc rrfsrcncc numhcn; 
AIMS = APSAC lnwvcntion Mnrtaliry sludy; 
APSAC = anistrcplaw (aniuyla~cd plasmirqcn 
strcpwkinaw aclivator complcxt, ASSET = Angb 
Srandinartin Study of Farty ThrumMysi~ EC56 = 
European Cwpcralivc Study Group: GISSI = 
(iruppn llaliantb per lo Studio dclla Strcpttn+inasi 
nctl’lnfarro Miwudicu: GIW-2 y Gruppo I~aliam 
pr lo Studio dclla !iopraw?viwza ncll‘lnfartc~ Mb 
car&w: GIISTO = What UtilbaGon cB Swqruki- 
nasc and I-PA for Occluded Coronary Ar~eriw 
ISIS = International Study of Infam Sun&al; SK = 
srrcptokinase: TIM II = Thrnmh$sis in Mytwrar- 
dial Infarcrion Phase II !+I: IPA = tissue-type 
pla3mmiw~4 ibclivalor. 
Fqure 3. In-hospital mortality raps for caw series 
studies of primary angioplasty for cardiugenic shock. 
Numbrrs in hack& arc rcfcrcnre numbers. 
Ferr 4. One- and S-year wrvival rates arn”‘lg all 
enrolled patients (WI only hrspitat survivors) ir- wdics 
ofptirnaqar@opMyandthranhoty&Nwabusin 
m arc rcferencr numbcn. TAMI = Thrombol- 
ysis and A@q&sty in Myocardii lnfarctbn trial: 
other aMrwiatior~ as in Figures I and 2 
One-year reinfarction rates arc shown in Table AJ. Rates of 
coronary bypass graft surgq and angioplacty are shown in 
Table 5. 
Question 4. Stroke (TaMe 6). What arc rates of hcmor- 
rhagic stroke and all strokes comhincd after I) primary angio- 
pbsty. ?) thromholysis, or 3) no intctwntion for mytwardisl 
intarction? 
Evidence Tables 
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